Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Gut ; 71(2): 309-321, 2022 02.
Artículo en Inglés | MEDLINE | ID: mdl-33687943

RESUMEN

OBJECTIVE: Chronic obstructive pulmonary disease (COPD) is a global disease characterised by chronic obstruction of lung airflow interfering with normal breathing. Although the microbiota of respiratory tract is established to be associated with COPD, the causality of gut microbiota in COPD development is not yet established. We aimed to address the connection between gut microbiota composition and lung COPD development, and characterise bacteria and their derived active components for COPD amelioration. DESIGN: A murine cigarette smoking (CS)-based model of COPD and strategies evaluating causal effects of microbiota were performed. Gut microbiota structure was analysed, followed by isolation of target bacterium. Single cell RNA sequencing, together with sera metabolomics analyses were performed to identify host responsive molecules. Bacteria derived active component was isolated, followed by functional assays. RESULTS: Gut microbiota composition significantly affects CS-induced COPD development, and faecal microbiota transplantation restores COPD pathogenesis. A commensal bacterium Parabacteroides goldsteinii was isolated and shown to ameliorate COPD. Reduction of intestinal inflammation and enhancement of cellular mitochondrial and ribosomal activities in colon, systematic restoration of aberrant host amino acids metabolism in sera, and inhibition of lung inflammations act as the important COPD ameliorative mechanisms. Besides, the lipopolysaccharide derived from P. goldsteinii is anti-inflammatory, and significantly ameliorates COPD by acting as an antagonist of toll-like receptor 4 signalling pathway. CONCLUSION: The gut microbiota-lung COPD axis was connected. A potentially benefial bacterial strain and its functional component may be developed and used as alternative agents for COPD prevention or treatment.


Asunto(s)
Bacteroidetes/aislamiento & purificación , Microbioma Gastrointestinal/fisiología , Enfermedad Pulmonar Obstructiva Crónica/etiología , Animales , Modelos Animales de Enfermedad , Trasplante de Microbiota Fecal , Lipopolisacáridos/metabolismo , Ratones , Ratones Endogámicos C57BL , Enfermedad Pulmonar Obstructiva Crónica/metabolismo , Enfermedad Pulmonar Obstructiva Crónica/patología , Fumar
2.
J Food Drug Anal ; 27(3): 615-622, 2019 07.
Artículo en Inglés | MEDLINE | ID: mdl-31324278

RESUMEN

Studies on the role of gut commensal bacteria in health development have rapidly attracted much more attention beyond the classical pathogens over the last decade. Many important reports have highlighted the changes in the gut microbiota (dysbiosis) are closely related to development of intra- and extra-intestinal, chronic inflammation related diseases such as colitis, obesity/metabolic syndromes, diabetes mellitus, liver diseases, cardiovascular diseases and also cancer and neurodegenerative diseases. To circumvent these difficulties, the strategy of modulating the structure of the gut microbiota has been under intensive study and shed more light on amelioration of these inflammation related diseases. While traditional probiotics generally show marginal ameliorative effects, emerging next generation probiotics start to reveal as new preventive and therapeutic tools. Recent studies have unraveled many potential next generation probiotics (NGP). These include Prevotella copri and Christensenella minuta that control insulin resistance, Parabacteroides goldsteinii, Akkermansia muciniphila and Bacteroides thetaiotaomicron that reverse obesity and insulin resistance, Faecalibacterium prausnitzii that protects mice against intestinal diseases, and Bacteroides fragilis that reduces inflammation and shows anticancer effect. New agents will soon be revealed for targeted therapy on specific inflammation related diseases. The important roles of next generation probiotics and gut microbiota normobiosis on the maintenance of intestinal integrity and homeostasis are emphasized.


Asunto(s)
Microbioma Gastrointestinal , Inflamación/microbiología , Inflamación/terapia , Probióticos/uso terapéutico , Animales , Enfermedades Cardiovasculares/terapia , Colitis/terapia , Diabetes Mellitus/terapia , Humanos , Hepatopatías/terapia , Síndrome Metabólico/terapia , Neoplasias/terapia , Enfermedades Neurodegenerativas/terapia , Obesidad/terapia
3.
J Biomed Sci ; 26(1): 3, 2019 Jan 04.
Artículo en Inglés | MEDLINE | ID: mdl-30609922

RESUMEN

Dysbiosis of gut microbiota is closely related to occurrence of many important chronic inflammations-related diseases. So far the traditionally prescribed prebiotics and probiotics do not show significant impact on amelioration of these diseases in general. Thus the development of next generation prebiotics and probiotics designed to target specific diseases is urgently needed. In this review, we first make a brief introduction on current understandings of normal gut microbiota, microbiome, and their roles in homeostasis of mucosal immunity and gut integrity. Then, under the situation of microbiota dysbiosis, development of chronic inflammations in the intestine occurs, leading to leaky gut situation and systematic chronic inflammation in the host. These subsequently resulted in development of many important diseases such as obesity, type 2 diabetes mellitus, liver inflammations, and other diseases such as colorectal cancer (CRC), obesity-induced chronic kidney disease (CKD), the compromised lung immunity, and some on brain/neuro disorders. The strategy used to optimally implant the effective prebiotics, probiotics and the derived postbiotics for amelioration of the diseases is presented. While the effectiveness of these agents seems promising, additional studies are needed to establish recommendations for most clinical settings.


Asunto(s)
Disbiosis/complicaciones , Microbioma Gastrointestinal/efectos de los fármacos , Inflamación/tratamiento farmacológico , Enfermedades Inflamatorias del Intestino/tratamiento farmacológico , Prebióticos/administración & dosificación , Probióticos/administración & dosificación , Humanos , Inflamación/inmunología , Inflamación/microbiología , Enfermedades Inflamatorias del Intestino/inmunología , Enfermedades Inflamatorias del Intestino/microbiología
4.
Gut ; 68(2): 248-262, 2019 02.
Artículo en Inglés | MEDLINE | ID: mdl-30007918

RESUMEN

OBJECTIVE: The medicinal fungus Ophiocordyceps sinensis and its anamorph Hirsutella sinensis have a long history of use in traditional Chinese medicine for their immunomodulatory properties. Alterations of the gut microbiota have been described in obesity and type 2 diabetes. We examined the possibility that H. sinensis mycelium (HSM) and isolated fractions containing polysaccharides may prevent diet-induced obesity and type 2 diabetes by modulating the composition of the gut microbiota. DESIGN: High-fat diet (HFD)-fed mice were treated with HSM or fractions containing polysaccharides of different molecular weights. The effects of HSM and polysaccharides on the gut microbiota were assessed by horizontal faecal microbiota transplantation (FMT), antibiotic treatment and 16S rDNA-based microbiota analysis. RESULTS: Fraction H1 containing high-molecular weight polysaccharides (>300 kDa) considerably reduced body weight gain (∼50% reduction) and metabolic disorders in HFD-fed mice. These effects were associated with increased expression of thermogenesis protein markers in adipose tissues, enhanced gut integrity, reduced intestinal and systemic inflammation and improved insulin sensitivity and lipid metabolism. Gut microbiota analysis revealed that H1 polysaccharides selectively promoted the growth of Parabacteroides goldsteinii, a commensal bacterium whose level was reduced in HFD-fed mice. FMT combined with antibiotic treatment showed that neomycin-sensitive gut bacteria negatively correlated with obesity traits and were required for H1's anti-obesogenic effects. Notably, oral treatment of HFD-fed mice with live P. goldsteinii reduced obesity and was associated with increased adipose tissue thermogenesis, enhanced intestinal integrity and reduced levels of inflammation and insulin resistance. CONCLUSIONS: HSM polysaccharides and the gut bacterium P. goldsteinii represent novel prebiotics and probiotics that may be used to treat obesity and type 2 diabetes.


Asunto(s)
Ascomicetos , Bacteroidetes/efectos de los fármacos , Bacteroidetes/fisiología , Diabetes Mellitus Tipo 2/prevención & control , Polisacáridos Fúngicos/farmacología , Microbioma Gastrointestinal/efectos de los fármacos , Obesidad/prevención & control , Animales , Dieta Alta en Grasa , Trasplante de Microbiota Fecal , Resistencia a la Insulina , Masculino , Ratones , Ratones Endogámicos C57BL , Peso Molecular , Prebióticos , Simbiosis
5.
J Immunol ; 201(5): 1478-1490, 2018 09 01.
Artículo en Inglés | MEDLINE | ID: mdl-30061197

RESUMEN

In developed countries, pulmonary nontuberculous mycobacteria (NTM) infections are more prevalent than Mycobacterium tuberculosis infections. Given the differences in the pathogenesis of NTM and M. tuberculosis infections, separate studies are needed to investigate the pathological effects of NTM pathogens. Our previous study showed that anti-IFN-γ autoantibodies are detected in NTM-infected patients. However, the role of NK cells and especially NK cell-derived IFN-γ in this context has not been studied in detail. In the current study, we show that NK1.1 cell depletion increases bacterial load and mortality in a mouse model of pulmonary NTM infection. NK1.1 cell depletion exacerbates NTM-induced pathogenesis by reducing macrophage phagocytosis, dendritic cell development, cytokine production, and lung granuloma formation. Similar pathological phenomena are observed in IFN-γ-deficient (IFN-γ-/-) mice following NTM infection, and adoptive transfer of wild-type NK cells into IFN-γ-/- mice considerably reduces NTM pathogenesis. Injection of rIFN-γ also prevents NTM-induced pathogenesis in IFN-γ-/- mice. We observed that NK cells represent the main producers of IFN-γ in the lungs and production starts as soon as 1 d postinfection. Accordingly, injection of rIFN-γ into IFN-γ-/- mice 1 d (but not 2 wk) postinfection significantly improves immunity against NTM infection. NK cells also stimulate mycobacterial killing and IL-12 production by macrophages. Our results therefore indicate that IFN-γ production by NK cells plays an important role in activating and enhancing innate and adaptive immune responses at early stages of pulmonary NTM infection.


Asunto(s)
Inmunidad Innata , Interferón gamma/inmunología , Células Asesinas Naturales/inmunología , Pulmón/inmunología , Infecciones por Mycobacterium no Tuberculosas/inmunología , Mycobacterium/inmunología , Neumonía Bacteriana/inmunología , Inmunidad Adaptativa/genética , Animales , Interferón gamma/deficiencia , Interleucina-12/genética , Interleucina-12/inmunología , Células Asesinas Naturales/patología , Pulmón/microbiología , Pulmón/patología , Ratones , Ratones Noqueados , Infecciones por Mycobacterium no Tuberculosas/genética , Infecciones por Mycobacterium no Tuberculosas/patología , Neumonía Bacteriana/patología
6.
Brain Behav Immun ; 69: 1-8, 2018 03.
Artículo en Inglés | MEDLINE | ID: mdl-28888668

RESUMEN

Depression is a mental disorder associated with environmental, genetic and psychological factors. Recent studies indicate that chronic neuro-inflammation may affect brain physiology and alter mood and behavior. Consumption of a high-fat diet leads to obesity and chronic systemic inflammation. The gut microbiota mediates many effects of a high-fat diet on human physiology and may also influence the mood and behavior of the host. We review here recent studies suggesting the existence of a link between obesity, the gut microbiota and depression, focusing on the mechanisms underlying the effects of a high-fat diet on chronic inflammation and brain physiology. This body of research suggests that modulating the composition of the gut microbiota using prebiotics and probiotics may produce beneficial effects on anxiety and depression.


Asunto(s)
Depresión/psicología , Microbioma Gastrointestinal/fisiología , Inflamación/psicología , Obesidad/psicología , Barrera Hematoencefálica , Depresión/microbiología , Dieta Alta en Grasa , Humanos , Inflamación/microbiología , Obesidad/microbiología
8.
J Ethnopharmacol ; 201: 117-122, 2017 Apr 06.
Artículo en Inglés | MEDLINE | ID: mdl-28167294

RESUMEN

ETHNOPHARMACOLOGICAL RELEVANCE: The medicinal mushroom Antrodia cinnamomea possesses anticancer properties but the active compounds responsible for these effects are mostly unknown. AIM OF THE STUDY: We aimed to identify novel A. cinnamomea compounds that produce cytotoxic effects on cancer cells. MATERIALS AND METHODS: Using ethanol extraction and chromatography, we isolated the lanostanoid compound lanosta-7,9(11),24-trien-3ß,15α,21-triol (1) from cultured A. cinnamomea mycelium. Cytotoxicity and pro-apoptotic effects of compound 1 were evaluated using the MTS assay and flow cytometry analysis, respectively. RESULTS: Compound 1 produced cytotoxic effects on the nasopharyngeal carcinoma cell lines TW02 and TW04, with IC50 values of 63.3 and 115.0µM, respectively. On the other hand, no cytotoxic effects were observed on non-tumorigenic nasopharyngeal epithelial cells (NP69). In addition, compound 1 induced apoptosis in TW02 and TW04 cells as revealed by flow cytometry analysis. CONCLUSIONS: Our results demonstrate for the first time the presence of pinicolol B in A. cinnamomea mycelium and suggest that this compound may contribute to the anticancer effects of A. cinnamomea.


Asunto(s)
Antineoplásicos/farmacología , Antrodia , Triterpenos/farmacología , Apoptosis/efectos de los fármacos , Carcinoma/tratamiento farmacológico , Línea Celular , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Humanos , Micelio , Carcinoma Nasofaríngeo , Neoplasias Nasofaríngeas/tratamiento farmacológico
9.
Sci Rep ; 6: 36747, 2016 11 15.
Artículo en Inglés | MEDLINE | ID: mdl-27845335

RESUMEN

Iron availability affects swarming and biofilm formation in various bacterial species. However, how bacteria sense iron and coordinate swarming and biofilm formation remains unclear. Using Serratia marcescens as a model organism, we identify here a stage-specific iron-regulatory machinery comprising a two-component system (TCS) and the TCS-regulated iron chelator 2-isocyano-6,7-dihydroxycoumarin (ICDH-Coumarin) that directly senses and modulates environmental ferric iron (Fe3+) availability to determine swarming initiation and biofilm formation. We demonstrate that the two-component system RssA-RssB (RssAB) directly senses environmental ferric iron (Fe3+) and transcriptionally modulates biosynthesis of flagella and the iron chelator ICDH-Coumarin whose production requires the pvc cluster. Addition of Fe3+, or loss of ICDH-Coumarin due to pvc deletion results in prolonged RssAB signaling activation, leading to delayed swarming initiation and increased biofilm formation. We further show that ICDH-Coumarin is able to chelate Fe3+ to switch off RssAB signaling, triggering swarming initiation and biofilm reduction. Our findings reveal a novel cellular system that senses iron levels to regulate bacterial surface lifestyle.


Asunto(s)
Proteínas Bacterianas/fisiología , Biopelículas , Hierro/metabolismo , Serratia marcescens/fisiología , Fenómenos Fisiológicos Bacterianos , Proteínas Bacterianas/genética , Proteínas Bacterianas/metabolismo , Cumarinas/metabolismo , Flagelos/genética , Flagelos/metabolismo , Flagelos/fisiología , Regulación Bacteriana de la Expresión Génica , Modelos Biológicos , Serratia marcescens/genética , Serratia marcescens/metabolismo , Transducción de Señal/genética , Transducción de Señal/fisiología
10.
Nat Commun ; 6: 7489, 2015 Jun 23.
Artículo en Inglés | MEDLINE | ID: mdl-26102296

RESUMEN

Obesity is associated with low-grade chronic inflammation and intestinal dysbiosis. Ganoderma lucidum is a medicinal mushroom used in traditional Chinese medicine with putative anti-diabetic effects. Here, we show that a water extract of Ganoderma lucidum mycelium (WEGL) reduces body weight, inflammation and insulin resistance in mice fed a high-fat diet (HFD). Our data indicate that WEGL not only reverses HFD-induced gut dysbiosis-as indicated by the decreased Firmicutes-to-Bacteroidetes ratios and endotoxin-bearing Proteobacteria levels-but also maintains intestinal barrier integrity and reduces metabolic endotoxemia. The anti-obesity and microbiota-modulating effects are transmissible via horizontal faeces transfer from WEGL-treated mice to HFD-fed mice. We further show that high molecular weight polysaccharides (>300 kDa) isolated from the WEGL extract produce similar anti-obesity and microbiota-modulating effects. Our results indicate that G. lucidum and its high molecular weight polysaccharides may be used as prebiotic agents to prevent gut dysbiosis and obesity-related metabolic disorders in obese individuals.


Asunto(s)
Medicamentos Herbarios Chinos/farmacología , Polisacáridos Fúngicos/farmacología , Microbioma Gastrointestinal/efectos de los fármacos , Resistencia a la Insulina , Obesidad/microbiología , Reishi , Animales , Bacteroides/efectos de los fármacos , Peso Corporal/efectos de los fármacos , Dieta Alta en Grasa , Disbiosis/metabolismo , Disbiosis/microbiología , Endotoxemia , Trasplante de Microbiota Fecal , Firmicutes/efectos de los fármacos , Inflamación/metabolismo , Inflamación/microbiología , Mucosa Intestinal/metabolismo , Intestinos/efectos de los fármacos , Ratones , Obesidad/metabolismo , Permeabilidad/efectos de los fármacos , Extractos Vegetales/farmacología , Proteobacteria/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...